Vaughns Janelle D, Martin Celeste, Nelson Jonathon, Nadler Evan, Quezado Zenaide M
Department of Anesthesiology, Pain and Perioperative Medicine and Pediatric Clinical Pharmacology, Children's Research Institute, Children's National Health System.
Department of Anesthesiology, Pain and Preoperative Medicine, Children's Research Institute, Children's National Health System.
J Pediatr Surg. 2017 Nov;52(11):1787-1790. doi: 10.1016/j.jpedsurg.2017.04.007. Epub 2017 Apr 19.
The anesthetic management of adolescents undergoing bariatric surgery presents a number of challenges, including increased risk of postoperative opioid-related respiratory depression. These patients could benefit from adjunctive analgesics with opioid-sparring effects to optimize perioperative pain control. Dexmedetomidine, a selective α2-adrenoreceptor agonist, has sedative and analgesic properties with no respiratory depressant effects.
To determine the effect of intraoperative dexmedetomidine on opioid requirement and perioperative pain management in obese adolescents undergoing bariatric surgery.
An observational study of 26 consecutive patients treated with and without dexmedetomidine during the intraoperative period was conducted. The dexmedetomidine treated patients received a loading dose over 30min and a continuous infusion thereafter. The standard group represented patients who received an institutional standard anesthetic without dexmedetomidine. The primary outcome was total perioperative intravenous morphine equivalent (MEq). We also examined reported pain scores during the perioperative period.
While there were no significant differences in age, height and weight category, there were imbalances on race distribution between the two groups. Both groups received similar doses of ketorolac and acetaminophen perioperatively. Overall, during 48h postoperatively, the dexmedetomidine group received significantly less total MEq administration compared with the standard group. Three patients in the dexmedetomidine group required ephedrine to treat an episode of hypotension.
These results suggest that the use of dexmedetomidine during bariatric surgery in the morbidly obese adolescent population is associated with decreased opioid utilization during the perioperative period. Future randomized studies will determine the role of dexmedetomidine in the pain management of obese adolescents undergoing bariatric surgery.
Therapeutic, Level III.
肥胖青少年接受减肥手术的麻醉管理存在诸多挑战,包括术后阿片类药物相关呼吸抑制风险增加。这些患者可能受益于具有阿片类药物节省效应的辅助镇痛药,以优化围手术期疼痛控制。右美托咪定是一种选择性α2肾上腺素能受体激动剂,具有镇静和镇痛特性,无呼吸抑制作用。
确定术中使用右美托咪定对肥胖青少年接受减肥手术时阿片类药物需求及围手术期疼痛管理的影响。
对26例在术中接受或未接受右美托咪定治疗的连续患者进行观察性研究。接受右美托咪定治疗的患者在30分钟内给予负荷剂量,随后持续输注。标准组为接受机构标准麻醉但未使用右美托咪定的患者。主要结局是围手术期静脉注射吗啡等效总量(MEq)。我们还检查了围手术期报告的疼痛评分。
虽然两组在年龄、身高和体重类别方面无显著差异,但在种族分布上存在不平衡。两组围手术期接受的酮咯酸和对乙酰氨基酚剂量相似。总体而言,术后48小时内,右美托咪定组与标准组相比,接受的MEq总量显著更少。右美托咪定组有3例患者需要麻黄碱治疗低血压发作。
这些结果表明,在病态肥胖青少年人群的减肥手术中使用右美托咪定与围手术期阿片类药物使用减少有关。未来的随机研究将确定右美托咪定在肥胖青少年接受减肥手术疼痛管理中的作用。
治疗性,三级。